Travere Therapeutics Dirección

Dirección controles de criterios 2/4

El CEO de Travere Therapeutics' es Eric Dube , nombrado en Jan 2019, tiene una permanencia de 5.42 años. compensación anual total es $7.57M, compuesta por 10.5% salario y 89.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.14% de las acciones de la empresa, por valor de $800.71K. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 7.2 años, respectivamente.

Información clave

Eric Dube

Chief Executive Officer (CEO)

US$7.6m

Compensación total

Porcentaje del salario del CEO	10.5%
Permanencia del CEO	5.4yrs
Participación del CEO	0.1%
Permanencia media de la dirección	2.8yrs
Promedio de permanencia en la Junta Directiva	7.2yrs

Actualizaciones recientes de la dirección

Shareholders May Be More Conservative With Travere Therapeutics, Inc.'s (NASDAQ:TVTX) CEO Compensation For Now

May 02

Recent updates

Shareholders May Be More Conservative With Travere Therapeutics, Inc.'s (NASDAQ:TVTX) CEO Compensation For Now

May 02

Lacklustre Performance Is Driving Travere Therapeutics, Inc.'s (NASDAQ:TVTX) 29% Price Drop

Apr 20

Travere Therapeutics: Restructuring Away From Disaster

Jan 30

Travere Therapeutics (NASDAQ:TVTX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Jan 22

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 48% But Its Business Prospects Need A Lift Too

Dec 18

New Forecasts: Here's What Analysts Think The Future Holds For Travere Therapeutics, Inc. (NASDAQ:TVTX)

Aug 08

Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Jun 09

It's Down 27% But Travere Therapeutics, Inc. (NASDAQ:TVTX) Could Be Riskier Than It Looks

May 05

Travere Therapeutics GAAP EPS of -$1.05 misses by $0.14, revenue of $54.2M beats by $4.7M

Aug 04

Travere Theraspeutics a new buy at Canaccord as a 'rare disease powerhouse'

Jul 14

Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?

Jun 19

Travere Therapeutics: Strong Sell, Ticking Time Bomb, We Are Passing

Apr 11

Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Feb 07

Travere Therapeutics: Tarpeyo's Approval Is Good News

Jan 31

Does Travere Therapeutics (NASDAQ:TVTX) Have A Healthy Balance Sheet?

Oct 07

Regulatory Uncertainty Holding Travere Therapeutics Down Despite PROTECT Study Success

Aug 30

Travere: Setback Presents Cautious Opportunity

Jul 18

Does Travere Therapeutics (NASDAQ:TVTX) Have A Healthy Balance Sheet?

Jul 09

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Eric Dube en comparación con los beneficios de Travere Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$416m
Dec 31 2023	US$8m	US$796k	-US$376m
Sep 30 2023	n/a	n/a	-US$320m
Jun 30 2023	n/a	n/a	-US$315m
Mar 31 2023	n/a	n/a	-US$352m
Dec 31 2022	US$6m	US$747k	-US$331m
Sep 30 2022	n/a	n/a	-US$297m
Jun 30 2022	n/a	n/a	-US$249m
Mar 31 2022	n/a	n/a	-US$202m
Dec 31 2021	US$6m	US$708k	-US$217m
Sep 30 2021	n/a	n/a	-US$250m
Jun 30 2021	n/a	n/a	-US$237m
Mar 31 2021	n/a	n/a	-US$224m
Dec 31 2020	US$5m	US$661k	-US$169m
Sep 30 2020	n/a	n/a	-US$78m
Jun 30 2020	n/a	n/a	-US$92m
Mar 31 2020	n/a	n/a	-US$105m
Dec 31 2019	US$10m	US$618k	-US$146m

Compensación vs. Mercado: La compensación total de Eric($USD7.57M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD2.44M).

Compensación vs. Ingresos: La compensación de Eric ha aumentado mientras la empresa no es rentable.

CEO

Eric Dube (51 yo)

5.4yrs

Permanencia

US$7,574,959

Compensación

Dr. Eric M. Dube, Ph D., serves as an Independent Director at Reneo Pharmaceuticals, Inc. since March 2021. Dr. Dube serves as President and Chief Executive Officer at Travere Therapeutics, Inc. (formerly...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Eric Dube	President	5.4yrs	US$7.57m	0.14% $ 798.5k
Christopher Cline	Chief Financial Officer	1.8yrs	US$1.97m	0.093% $ 517.9k
Elizabeth Reed	Senior VP	7.4yrs	US$2.02m	0.036% $ 200.4k
William Rote	Senior VP and Head of Research & Development	7.3yrs	US$2.05m	0.042% $ 232.9k
Peter Heerma	Chief Commercial Officer	4.7yrs	US$2.00m	0.067% $ 370.2k
Sandra Calvin	SVP, Corporate Controller & Chief Accounting Officer	2.8yrs	sin datos	0.068% $ 380.3k
Naomi Eichenbaum	Vice President of Investor Relations	no data	sin datos	sin datos
Charlotte Smith	Senior Vice President of Public Affairs	1.7yrs	sin datos	sin datos
Angela Giannantonio	Senior Vice President of Human Resources	no data	sin datos	sin datos
Casey Logan	Chief Business Officer	less than a year	sin datos	sin datos
Jula Inrig	Chief Medical Officer	2.4yrs	US$2.87m	0.076% $ 424.5k

2.8yrs

Permanencia media

52yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de TVTX se considera experimentado (2.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Eric Dube	President	5.4yrs	US$7.57m	0.14% $ 798.5k
John Orwin	Independent Director	7.3yrs	US$372.98k	0.038% $ 211.1k
Gary Lyons	Independent Chairman of the Board	9.7yrs	US$392.98k	0.067% $ 372.8k
Stuart J. Swiedler	Member of Scientific Advisory Board	no data	sin datos	sin datos
Suzanne Bruhn	Independent Director	4.2yrs	US$372.36k	0.029% $ 162.7k
Roy Baynes	Independent Director	8yrs	US$376.73k	0.041% $ 226.6k
Ruth Williams-Brinkley	Independent Director	2.8yrs	US$365.48k	0.025% $ 140.7k
Timothy Coughlin	Independent Director	9.3yrs	US$385.48k	0.064% $ 358.2k
Ron Squarer	Independent Director	7.2yrs	US$367.98k	0.038% $ 211.1k
Jeffrey Meckler	Independent Director	9.7yrs	US$379.98k	0.11% $ 592.1k
Alan Beggs	Member of Scientific Advisory Board	no data	sin datos	sin datos
Sandra Poole	Independent Director	5.1yrs	US$369.86k	0.031% $ 171.8k

7.2yrs

Permanencia media

60yo

Promedio de edad

Junta con experiencia: La junta directiva de TVTX se considera experimentada (7.2 años de antigüedad promedio).

Travere Therapeutics Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Shareholders May Be More Conservative With Travere Therapeutics, Inc.'s (NASDAQ:TVTX) CEO Compensation For Now

Travere Therapeutics, Inc., Annual General Meeting, May 08, 2024

President recently sold US$78k worth of stock

President notifies of intention to sell stock

Insufficient new directors

President notifies of intention to sell stock

Recent updates

Forecast to breakeven in 2026

Consensus EPS estimates fall by 13%, revenue upgraded

New minor risk - Profitability

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Forecast to breakeven in 2026

Shareholders May Be More Conservative With Travere Therapeutics, Inc.'s (NASDAQ:TVTX) CEO Compensation For Now

Travere Therapeutics, Inc. to Report Q1, 2024 Results on May 06, 2024

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

Lacklustre Performance Is Driving Travere Therapeutics, Inc.'s (NASDAQ:TVTX) 29% Price Drop

Travere Therapeutics to Present Abstracts on Filspari® (Sparsentan) in Iga Nephropathy At World Congress of Nephrology and the American Nephrology Nurses Association

Travere Therapeutics, Inc., Annual General Meeting, May 08, 2024

Travere Therapeutics, Inc. Submits Supplemental New Drug Application to U.S. Food and Drug Administration Seeking Full Approval of FILSPARI (Sparsentan) for Treatment of IgA Nephropathy

Travere Therapeutics, Inc. and Csl Vifor Announce Sparsentan Receives Positive Chmp Opinion for the Treatment of Iga Nephropathy

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates upgraded to US$1.86 loss

Travere Therapeutics, Inc. to Report Q4, 2023 Results on Feb 15, 2024

President recently sold US$78k worth of stock

President notifies of intention to sell stock

Travere Therapeutics: Restructuring Away From Disaster

Travere Therapeutics (NASDAQ:TVTX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Travere Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 48% But Its Business Prospects Need A Lift Too

Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)

Consensus EPS estimates fall by 35%

Travere Therapeutics, Inc. Completes Successful Pre-NDA Meeting for FILSPARI in IgAN

Consensus EPS estimates upgraded to US$1.55 loss

Consensus revenue estimates decrease by 16%, EPS upgraded

New major risk - Share price stability

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Travere Therapeutics, Inc. Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and Fs Published in the Lancet and the NEJM Respectively and Presented At the American Society of Nephrology Kidney Week 2023

Travere Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Travere Therapeutics Announces Confirmatory Data from the Phase 3 Protect Study of Filspari Demonstrating Long-Term Kidney Function Preservation in Iga Nephropathy; Narrowly Missing Egfr Total Slope Endpoint Versus Active Control, Irbesartan

Price target decreased by 17% to US$22.40

Mirum Pharmaceuticals, Inc. (NasdaqGM:MIRM) completed the acquisition of Bile Acid Product Portfolio from Travere Therapeutics, Inc. (NasdaqGM:TVTX).

Mirum Pharmaceuticals, Inc. (NasdaqGM:MIRM) completed the acquisition of Bile Acid Product Portfolio from Travere Therapeutics, Inc. (NasdaqGM:TVTX).

Consensus revenue estimates increase by 10%

New Forecasts: Here's What Analysts Think The Future Holds For Travere Therapeutics, Inc. (NASDAQ:TVTX)

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Travere Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Travere Therapeutics, Inc. Announces Positive Topline Results from Cohort 6 in the Phase 1/2 Compose Study of Pegtibatinase in Classical Homocystinuria

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

It's Down 27% But Travere Therapeutics, Inc. (NASDAQ:TVTX) Could Be Riskier Than It Looks

Price target decreased by 17% to US$29.33

Insufficient new directors

Consensus EPS estimates fall by 16%

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Price target increased by 7.2% to US$35.83

Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI(sparsentan), the First and Only Non-Immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

Travere Therapeutics, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

President notifies of intention to sell stock

Travere Therapeutics, Inc. Provides Financial Guidance for the Fourth Quarter and for the Fiscal Year 2022

President notifies of intention to sell stock

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Travere Therapeutics, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Price target decreased to US$33.90

Travere Therapeutics Provides Regulatory Update on Its Sparsentan Program for Iga Nephropathy

Travere Therapeutics' FDA target action date for nephropathy treatment extended

Chief Commercial Officer recently sold US$78k worth of stock

Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?

Travere Therapeutics: Changes In The Risk-Reward Assessment

Travere Therapeutics, Inc. and Csl Vifor Announce Ema Has Accepted for Review the Conditional Marketing Authorization Application for Sparsentan for the Treatment of Iga Nephropathy

Travere, CSL kidney disease drug sparsentan gets review in EU

Travere Therapeutics, Inc. Announces Executive Changes

Price target decreased to US$37.33

Second quarter 2022 earnings released: US$1.05 loss per share (vs US$0.64 loss in 2Q 2021)

Travere Therapeutics Provides Regulatory Updates on its Development Programs

Travere Therapeutics GAAP EPS of -$1.05 misses by $0.14, revenue of $54.2M beats by $4.7M